Chinese life-science reagent supplier making recombinant proteins and antibodies used in biopharma R&D, diagnostics and vaccine development.
Chinese life-science reagent supplier making recombinant proteins and antibodies used in biopharma R&D, diagnostics and vaccine development.
Sells off-the-shelf research proteins and antibodies, ordered by lab scientists in small lots, and higher-grade versions made to manufacturing standards for drugmakers, so revenue builds on a wide catalog and repeat purchasing. Customers range from large drug developers to academic labs, and a sizeable share of sales is exported.
In one line: A Chinese Bio-Techne/R&D Systems.
Moat: narrow (scale, process know-how, installed base). Broad, validated catalog of research-grade proteins used across many biopharma R&D pipelines.
Headquarters: Beijing, China · Employees: 926
Size Acrobiosystems (301080.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.31B, the 1039th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥74.21 on 18 Nov 2026.
Performance Over six months the shares gained 65.3%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 29.1% over the last twelve months (peer median +4.2%); the operating margin is 17.2% (peer median 9.1%).
Valuation It trades at 55.2× forward earnings against a peer median of 21.6× (3rd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.2 points below its cost of capital (11.6% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.03B | CN¥837M | CN¥644M | CN¥543M | CN¥474M |
| Revenue growth | — | +30% | +19% | +15% | — |
| Gross profit | CN¥945M | CN¥710M | CN¥538M | CN¥456M | CN¥414M |
| EBITDA | n/a | CN¥204M | CN¥131M | CN¥137M | CN¥160M |
| Net income | CN¥195M | CN¥166M | CN¥124M | CN¥154M | CN¥204M |
| Free cash flow | CN¥206M | CN¥255M | -CN¥82.4M | -CN¥12.2M | -CN¥61.0M |
| Capital expenditure | CN¥236M | CN¥205M | CN¥167M | CN¥129M | CN¥284M |
| Total debt | CN¥129M | CN¥122M | CN¥143M | CN¥102M | CN¥71.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Acrobiosystems 301080.SZ | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% |
| Sino Biological 301047.SZ | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% |
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301080.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.9% | -4.4% | 4th lowest of 21 |
| 6-month return | +65.3% | -11.5% | highest of 21 |
| Distance from 52-week high | -47.4% | -30.8% | 6th lowest of 21 |
| Revenue growth (TTM) | +29.1% | +4.2% | 3rd highest of 20 |
| Operating margin | 17.2% | 9.1% | 6th highest of 19 |
| Forward P/E | 55.2× | 21.6× | 3rd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 41.3% | 2.8% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +27.7% | +6.5% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | +13.6 pp | -0.5 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | -1.2 pp | -1.3 pp | 8th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |